Forskning ved Københavns Universitet - Københavns Universitet

Forside

Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. / Jones, Sophie; Grignard, Lynn; Nebie, Issa; Chilongola, Jaffu; Dodoo, Daniel; Sauerwein, Robert; Theisen, Michael; Roeffen, Will; Singh, Shrawan Kumar; Singh, Rajesh Kumar; Singh, Sanjay; Kyei-Baafour, Eric; Tetteh, Kevin; Drakeley, Chris; Bousema, Teun.

I: Journal of Infection, Bind 71, Nr. 1, 07.2015, s. 117-27.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jones, S, Grignard, L, Nebie, I, Chilongola, J, Dodoo, D, Sauerwein, R, Theisen, M, Roeffen, W, Singh, SK, Singh, RK, Singh, S, Kyei-Baafour, E, Tetteh, K, Drakeley, C & Bousema, T 2015, 'Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates', Journal of Infection, bind 71, nr. 1, s. 117-27. https://doi.org/10.1016/j.jinf.2015.03.007

APA

Jones, S., Grignard, L., Nebie, I., Chilongola, J., Dodoo, D., Sauerwein, R., ... Bousema, T. (2015). Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. Journal of Infection, 71(1), 117-27. https://doi.org/10.1016/j.jinf.2015.03.007

Vancouver

Jones S, Grignard L, Nebie I, Chilongola J, Dodoo D, Sauerwein R o.a. Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. Journal of Infection. 2015 jul;71(1):117-27. https://doi.org/10.1016/j.jinf.2015.03.007

Author

Jones, Sophie ; Grignard, Lynn ; Nebie, Issa ; Chilongola, Jaffu ; Dodoo, Daniel ; Sauerwein, Robert ; Theisen, Michael ; Roeffen, Will ; Singh, Shrawan Kumar ; Singh, Rajesh Kumar ; Singh, Sanjay ; Kyei-Baafour, Eric ; Tetteh, Kevin ; Drakeley, Chris ; Bousema, Teun. / Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates. I: Journal of Infection. 2015 ; Bind 71, Nr. 1. s. 117-27.

Bibtex

@article{d7c88b8ec98d4ef8884187e053a6d50a,
title = "Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates",
abstract = "OBJECTIVES: Pfs48/45 and Pfs230 are Plasmodium falciparum sexual stage proteins and promising malaria transmission-blocking vaccine candidates. Antibody responses against these proteins may be naturally acquired and target antigens may be under selective pressure. This has consequences for the future evaluation of vaccine immunogenicity and efficacy in populations naturally exposed to malaria.METHODS: We determined naturally acquired antibody responses to the recombinant proteins Pfs48/45-10C and Pfs230-230CMB in children from three malaria endemic settings in Ghana, Tanzania and Burkina Faso. We also examined genetic polymorphisms in the P. falciparum gene pfs48/45.RESULTS: Antibody prevalence was 1.1-18.2{\%} for 10C and 6.7-18.9{\%} for 230CMB. In Burkina Faso we observed evidence of an age-dependent acquisition pattern for both 10C (p < 0.001) and 230CMB (p = 0.031). Membrane feeding assays on a separate dataset demonstrated an association between functional transmission reducing activity and antibody prevalence for both 10C (p = 0.017) and 230CMB (p = 0.049). 17 single nucleotide polymorphisms were found in pfs48/45 (from 126 samples), with 5 non-synonymous SNPs in the Pfs48/45 10C region.CONCLUSIONS: We conclude there are naturally acquired antibody responses to both vaccine candidates which have functional relevance by reducing the transmissibility of infected individuals. We identified genetic polymorphisms, in pfs48/45 which exhibited geographical specificity.",
author = "Sophie Jones and Lynn Grignard and Issa Nebie and Jaffu Chilongola and Daniel Dodoo and Robert Sauerwein and Michael Theisen and Will Roeffen and Singh, {Shrawan Kumar} and Singh, {Rajesh Kumar} and Sanjay Singh and Eric Kyei-Baafour and Kevin Tetteh and Chris Drakeley and Teun Bousema",
note = "Copyright {\circledC} 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.",
year = "2015",
month = "7",
doi = "10.1016/j.jinf.2015.03.007",
language = "English",
volume = "71",
pages = "117--27",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B.Saunders Co. Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

AU - Jones, Sophie

AU - Grignard, Lynn

AU - Nebie, Issa

AU - Chilongola, Jaffu

AU - Dodoo, Daniel

AU - Sauerwein, Robert

AU - Theisen, Michael

AU - Roeffen, Will

AU - Singh, Shrawan Kumar

AU - Singh, Rajesh Kumar

AU - Singh, Sanjay

AU - Kyei-Baafour, Eric

AU - Tetteh, Kevin

AU - Drakeley, Chris

AU - Bousema, Teun

N1 - Copyright © 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

PY - 2015/7

Y1 - 2015/7

N2 - OBJECTIVES: Pfs48/45 and Pfs230 are Plasmodium falciparum sexual stage proteins and promising malaria transmission-blocking vaccine candidates. Antibody responses against these proteins may be naturally acquired and target antigens may be under selective pressure. This has consequences for the future evaluation of vaccine immunogenicity and efficacy in populations naturally exposed to malaria.METHODS: We determined naturally acquired antibody responses to the recombinant proteins Pfs48/45-10C and Pfs230-230CMB in children from three malaria endemic settings in Ghana, Tanzania and Burkina Faso. We also examined genetic polymorphisms in the P. falciparum gene pfs48/45.RESULTS: Antibody prevalence was 1.1-18.2% for 10C and 6.7-18.9% for 230CMB. In Burkina Faso we observed evidence of an age-dependent acquisition pattern for both 10C (p < 0.001) and 230CMB (p = 0.031). Membrane feeding assays on a separate dataset demonstrated an association between functional transmission reducing activity and antibody prevalence for both 10C (p = 0.017) and 230CMB (p = 0.049). 17 single nucleotide polymorphisms were found in pfs48/45 (from 126 samples), with 5 non-synonymous SNPs in the Pfs48/45 10C region.CONCLUSIONS: We conclude there are naturally acquired antibody responses to both vaccine candidates which have functional relevance by reducing the transmissibility of infected individuals. We identified genetic polymorphisms, in pfs48/45 which exhibited geographical specificity.

AB - OBJECTIVES: Pfs48/45 and Pfs230 are Plasmodium falciparum sexual stage proteins and promising malaria transmission-blocking vaccine candidates. Antibody responses against these proteins may be naturally acquired and target antigens may be under selective pressure. This has consequences for the future evaluation of vaccine immunogenicity and efficacy in populations naturally exposed to malaria.METHODS: We determined naturally acquired antibody responses to the recombinant proteins Pfs48/45-10C and Pfs230-230CMB in children from three malaria endemic settings in Ghana, Tanzania and Burkina Faso. We also examined genetic polymorphisms in the P. falciparum gene pfs48/45.RESULTS: Antibody prevalence was 1.1-18.2% for 10C and 6.7-18.9% for 230CMB. In Burkina Faso we observed evidence of an age-dependent acquisition pattern for both 10C (p < 0.001) and 230CMB (p = 0.031). Membrane feeding assays on a separate dataset demonstrated an association between functional transmission reducing activity and antibody prevalence for both 10C (p = 0.017) and 230CMB (p = 0.049). 17 single nucleotide polymorphisms were found in pfs48/45 (from 126 samples), with 5 non-synonymous SNPs in the Pfs48/45 10C region.CONCLUSIONS: We conclude there are naturally acquired antibody responses to both vaccine candidates which have functional relevance by reducing the transmissibility of infected individuals. We identified genetic polymorphisms, in pfs48/45 which exhibited geographical specificity.

U2 - 10.1016/j.jinf.2015.03.007

DO - 10.1016/j.jinf.2015.03.007

M3 - Journal article

C2 - 25869538

VL - 71

SP - 117

EP - 127

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

IS - 1

ER -

ID: 138856690